Teva Pharmaceutical Industries (TEVA) R&D Day 2026 summary
Event summary combining transcript, slides, and related documents.
R&D Day 2026 summary
15 Nov, 2026Pipeline overview and program updates
Pipeline includes 10 innovative assets, with seven late-stage programs representing more than $10B in combined peak-sales potential; four homegrown immunology programs include duvakitug, anti-IL-15, PD-1/IL-2 and TSLP/IL-13.
Duvakitug is advancing in ulcerative colitis, Crohn’s disease, hidradenitis suppurativa and fibrostenotic Crohn’s disease; anti-IL-15 spans celiac disease, vitiligo and alopecia areata.
Early antibody programs include TL1A/IL-23 and TSLP/IL-13, with additional engineered candidates in discovery.
Emrusolmin’s Phase 2 study is being discontinued after meeting its futility milestone; anti-TL1A/IL-23 was added to the preclinical pipeline.
Clinical trial data and development milestones
Anti-IL-15 Phase 2a celiac study met its Week 8 primary endpoint: less villus damage than placebo (p<0.05; n=43) and reduced inflammatory IEL markers; Phase 2b is planned for H2 2027.
In vitiligo, ~75% of patients reported facial improvement after two subcutaneous doses 12 weeks apart; 19 patients completed the proof-of-concept analysis. TEV-'408 is advancing to Phase 2/3.
Duvakitug Phase 2b showed placebo-adjusted clinical remission of 27.4% in ulcerative colitis at Week 14; cross-trial maintenance comparisons suggest potential, but are not head-to-head.
Anti-PD-1/IL-2 Phase 1 interim data in 25 participants showed one complete and six partial responses across 11 tumor types, with no safety signals reported by Oct. 29, 2026.
DARI Phase 3 enrollment exceeded 2,700, with >90% of required exacerbation events; ecopipam is filed with FDA, and approval is targeted for H1 2027.
R&D strategy and innovation priorities
R&D model prioritizes clinically validated biology, differentiated high-potential assets, unmet need, accelerated development and data-driven capital allocation.
Antibody engineering combines disease-biology insights with precision formats, including pH-tuned TL1A/IL-23 blockade and dual-specific TSLP/IL-13 design.
Accelerated development includes direct Phase 1-to-3 and seamless Phase 2/3 designs, with estimated time savings of 4 to >24 months across cited examples.
Launch cadence targets one innovative product annually through 2030, with up to nine marketed innovative assets by 2030, subject to approval.
Latest events from Teva Pharmaceutical Industries
- Innovative growth lifted margins and 2026 guidance despite generic erosion.TEVA
Q3 2026 - Revenue grew 6%, supported by growth brands and a $500M anti-TL1A payment, as debt declined.TEVA
Q4 2023 - FDA approves WELTRUZA, a once-monthly olanzapine LAI for adults with schizophrenia.TEVA
FDA announcement - Investment grade status enables accelerated innovation, robust launches, and renewed generics growth.TEVA
Bank of America Global Healthcare Conference - Biopharma transformation drives growth, margin expansion, and robust pipeline execution.TEVA
U.S. All Stars Conference - Biopharma transformation accelerates as innovative launches and biosimilars drive growth.TEVA
Barclays 24th Annual Global Financial Services Conference - Growth strategy delivers early milestones, with innovative products and biosimilars driving future value.TEVA
Morgan Stanley 24th Annual Global Healthcare Conference - TEV-408 significantly prevented gluten-induced intestinal damage and improved symptoms in celiac disease.TEVA
Study result - Innovative brands surged 43% YoY, offsetting generics decline, with 2026 outlook raised.TEVA
Q2 2026